US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5

$ 6.50

4.8
(710)
In stock
Description

Adiponectin-derived active peptide ADP355 exerts anti-inflammatory

CD352 (NTB-A) Antibody, anti-human, REAfinity™

CD352 (NTB-A) Antibody, anti-human, REAfinity™

CD5L is a pleiotropic player in liver fibrosis controlling damage

Investigating fibrosis and inflammation in an ex vivo NASH murine

Frontiers Nanotechnology in Drug Delivery for Liver Fibrosis

CD56 Antibody, anti-human, REAfinity™

In vivo production of CAR-T cells using CD5/LNP-FAPCAR

Frontiers SNS-032 attenuates liver fibrosis by anti-active

GDF15 deficiency exacerbates CCl 4-induced liver fibrosis. (a